<bill session="116" type="h" number="3" updated="2022-11-01T13:49:57Z">
  <state datetime="2019-12-12T14:09:56-05:00">PASS_OVER:HOUSE</state>
  <status>
    <unknown datetime="2019-12-12T14:09:56-05:00"/>
  </status>
  <introduced datetime="2019-09-19"/>
  <titles>
    <title type="display">Elijah E. Cummings Lower Drug Costs Now Act</title>
    <title type="official" as="introduced">To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.</title>
    <title type="short" as="introduced">Lower Drug Costs Now Act of 2019</title>
    <title type="short" as="reported to house">Elijah E. Cummings Lower Drug Costs Now Act</title>
    <title type="short" as="reported to house">Lower Drug Costs Now Act of 2019</title>
    <title type="short" as="passed house">Elijah E. Cummings Lower Drug Costs Now Act</title>
    <title type="short" as="passed house">Elijah E. Cummings Lower Drug Costs Now Act</title>
    <title type="short" as="passed house" partial="1">Home Visiting to Reduce Maternal Mortality and Morbidity Act</title>
    <title type="short" as="passed house" partial="1">Pathways to Health Careers Act</title>
  </titles>
  <sponsor bioguide_id="P000034"/>
  <cosponsors>
    <cosponsor bioguide_id="A000376" joined="2019-10-01"/>
    <cosponsor bioguide_id="A000378" joined="2019-11-01"/>
    <cosponsor bioguide_id="B001270" joined="2019-11-21"/>
    <cosponsor bioguide_id="B001281" joined="2019-10-08"/>
    <cosponsor bioguide_id="B001292" joined="2019-11-01"/>
    <cosponsor bioguide_id="B000490" joined="2019-11-26"/>
    <cosponsor bioguide_id="B001303" joined="2019-10-01"/>
    <cosponsor bioguide_id="B001278" joined="2019-09-26"/>
    <cosponsor bioguide_id="B001286" joined="2019-10-21"/>
    <cosponsor bioguide_id="C001112" joined="2019-09-26"/>
    <cosponsor bioguide_id="C001090" joined="2019-10-01"/>
    <cosponsor bioguide_id="C001055" joined="2019-09-24"/>
    <cosponsor bioguide_id="C001117" joined="2019-10-21"/>
    <cosponsor bioguide_id="C001066" joined="2019-09-25"/>
    <cosponsor bioguide_id="C001091" joined="2019-11-21"/>
    <cosponsor bioguide_id="C001080" joined="2019-10-31"/>
    <cosponsor bioguide_id="C001061" joined="2019-10-22"/>
    <cosponsor bioguide_id="C001068" joined="2019-10-01"/>
    <cosponsor bioguide_id="C001069" joined="2019-09-25"/>
    <cosponsor bioguide_id="C001119" joined="2019-10-11"/>
    <cosponsor bioguide_id="C001111" joined="2019-10-21"/>
    <cosponsor bioguide_id="C001063" joined="2019-10-21"/>
    <cosponsor bioguide_id="D000629" joined="2019-10-31"/>
    <cosponsor bioguide_id="D000096" joined="2019-10-16"/>
    <cosponsor bioguide_id="D000197" joined="2019-09-24"/>
    <cosponsor bioguide_id="D000610" joined="2019-11-08"/>
    <cosponsor bioguide_id="D000624" joined="2019-11-12"/>
    <cosponsor bioguide_id="D000482" joined="2019-10-16"/>
    <cosponsor bioguide_id="E000179" joined="2019-09-25"/>
    <cosponsor bioguide_id="E000215" joined="2019-10-08"/>
    <cosponsor bioguide_id="E000297" joined="2019-10-29"/>
    <cosponsor bioguide_id="E000296" joined="2019-09-25"/>
    <cosponsor bioguide_id="F000467" joined="2019-11-12"/>
    <cosponsor bioguide_id="F000468" joined="2019-12-06"/>
    <cosponsor bioguide_id="F000462" joined="2019-09-25"/>
    <cosponsor bioguide_id="G000559" joined="2019-11-13"/>
    <cosponsor bioguide_id="G000587" joined="2019-10-16"/>
    <cosponsor bioguide_id="G000592" joined="2019-10-11"/>
    <cosponsor bioguide_id="G000581" joined="2019-11-21"/>
    <cosponsor bioguide_id="H000324" joined="2019-11-01"/>
    <cosponsor bioguide_id="H001081" joined="2019-10-01"/>
    <cosponsor bioguide_id="H001038" joined="2019-10-30"/>
    <cosponsor bioguide_id="H001087" joined="2019-09-26"/>
    <cosponsor bioguide_id="H001066" joined="2019-10-08"/>
    <cosponsor bioguide_id="J000294" joined="2019-11-08"/>
    <cosponsor bioguide_id="K000375" joined="2019-10-11"/>
    <cosponsor bioguide_id="K000380" joined="2019-09-25"/>
    <cosponsor bioguide_id="K000394" joined="2019-10-01"/>
    <cosponsor bioguide_id="K000382" joined="2019-09-24"/>
    <cosponsor bioguide_id="L000559" joined="2019-10-30"/>
    <cosponsor bioguide_id="L000557" joined="2019-09-20"/>
    <cosponsor bioguide_id="L000586" joined="2019-10-28"/>
    <cosponsor bioguide_id="L000565" joined="2019-10-21"/>
    <cosponsor bioguide_id="L000579" joined="2019-12-05"/>
    <cosponsor bioguide_id="L000480" joined="2019-11-01"/>
    <cosponsor bioguide_id="L000562" joined="2019-10-29"/>
    <cosponsor bioguide_id="M001185" joined="2019-10-28"/>
    <cosponsor bioguide_id="M001163" joined="2019-10-16"/>
    <cosponsor bioguide_id="M001208" joined="2019-11-08"/>
    <cosponsor bioguide_id="M001143" joined="2019-11-13"/>
    <cosponsor bioguide_id="M001200" joined="2019-11-05"/>
    <cosponsor bioguide_id="M000312" joined="2019-09-25"/>
    <cosponsor bioguide_id="M001166" joined="2019-10-01"/>
    <cosponsor bioguide_id="M001137" joined="2019-10-29"/>
    <cosponsor bioguide_id="M001188" joined="2019-10-01"/>
    <cosponsor bioguide_id="M001160" joined="2019-09-25"/>
    <cosponsor bioguide_id="M001206" joined="2019-09-24"/>
    <cosponsor bioguide_id="M001207" joined="2019-10-21"/>
    <cosponsor bioguide_id="N000015" joined="2019-09-19"/>
    <cosponsor bioguide_id="N000188" joined="2019-09-25"/>
    <cosponsor bioguide_id="N000147" joined="2019-09-25"/>
    <cosponsor bioguide_id="P000614" joined="2019-09-26"/>
    <cosponsor bioguide_id="P000604" joined="2019-11-08"/>
    <cosponsor bioguide_id="P000593" joined="2019-10-31"/>
    <cosponsor bioguide_id="P000616" joined="2019-10-28"/>
    <cosponsor bioguide_id="R000613" joined="2019-10-01"/>
    <cosponsor bioguide_id="R000599" joined="2019-10-16"/>
    <cosponsor bioguide_id="R000515" joined="2019-09-24"/>
    <cosponsor bioguide_id="R000577" joined="2019-09-24"/>
    <cosponsor bioguide_id="S001177" joined="2019-09-24"/>
    <cosponsor bioguide_id="S001168" joined="2019-10-22"/>
    <cosponsor bioguide_id="S001205" joined="2019-11-08"/>
    <cosponsor bioguide_id="S001145" joined="2019-10-22"/>
    <cosponsor bioguide_id="S001150" joined="2019-10-11"/>
    <cosponsor bioguide_id="S001190" joined="2019-10-28"/>
    <cosponsor bioguide_id="S001216" joined="2019-10-21"/>
    <cosponsor bioguide_id="S000185" joined="2019-09-19"/>
    <cosponsor bioguide_id="S001206" joined="2019-09-24"/>
    <cosponsor bioguide_id="S001208" joined="2019-10-16"/>
    <cosponsor bioguide_id="S000510" joined="2019-12-03"/>
    <cosponsor bioguide_id="S001200" joined="2019-10-08"/>
    <cosponsor bioguide_id="S001209" joined="2019-11-08"/>
    <cosponsor bioguide_id="S001215" joined="2019-10-31"/>
    <cosponsor bioguide_id="S001201" joined="2019-10-08"/>
    <cosponsor bioguide_id="T000460" joined="2019-10-01"/>
    <cosponsor bioguide_id="T000474" joined="2019-11-08"/>
    <cosponsor bioguide_id="T000483" joined="2019-10-01"/>
    <cosponsor bioguide_id="V000131" joined="2019-11-13"/>
    <cosponsor bioguide_id="V000132" joined="2019-10-08"/>
    <cosponsor bioguide_id="V000108" joined="2019-09-26"/>
    <cosponsor bioguide_id="W000797" joined="2019-10-11"/>
    <cosponsor bioguide_id="W000800" joined="2019-10-16"/>
    <cosponsor bioguide_id="W000825" joined="2019-10-22"/>
    <cosponsor bioguide_id="W000826" joined="2019-10-08"/>
    <cosponsor bioguide_id="W000808" joined="2019-10-16"/>
    <cosponsor bioguide_id="Y000062" joined="2019-11-08"/>
  </cosponsors>
  <actions>
    <action datetime="2019-09-19">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-09-19" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-09-19">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-09-19">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-09-19">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2019-09-20">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2019-09-25">
      <text>Subcommittee Hearings Held.</text>
    </action>
    <action datetime="2019-10-17">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2019-10-17" state="REPORTED">
      <text>Ordered to be Reported by the Yeas and Nays: 30 - 22.</text>
    </action>
    <action datetime="2019-10-17">
      <text>Subcommittee on Health Discharged.</text>
    </action>
    <action datetime="2019-10-17">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2019-10-17">
      <text>Ordered to be Reported (Amended) by the Yeas and Nays: 27 - 21.</text>
    </action>
    <action datetime="2019-10-22">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2019-10-22">
      <text>Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 24 - 17.</text>
    </action>
    <action datetime="2019-12-06">
      <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-324, Part I.</text>
    </action>
    <action datetime="2019-12-06">
      <text>Reported (Amended) by the Committee on Ways and Means. H. Rept. 116-324, Part II.</text>
    </action>
    <action datetime="2019-12-06">
      <text>House Committee on Education and Labor Granted an extension for further consideration ending not later than Dec. 9, 2019.</text>
    </action>
    <action datetime="2019-12-09">
      <text>Reported (Amended) by the Committee on Education and Labor. H. Rept. 116-324, Part III.</text>
    </action>
    <calendar datetime="2019-12-09" calendar="Union" number="264">
      <text>Placed on the Union Calendar, Calendar No. 264.</text>
    </calendar>
    <action datetime="2019-12-10T21:16:40-05:00">
      <text>Rules Committee Resolution H. Res. 758 Reported to House. The rule provides for consideration of H.R. 3, under a structured rule, with 4 hours of general debate. The rule provides for consideration of H.R. 5038 under a closed rule, with 1 hour of general debate. The rule provides for consideration of the conference report to accompany S. 1790 with 1 hour of debate.</text>
    </action>
    <action datetime="2019-12-11T18:18:13-05:00">
      <text>Considered under the provisions of rule H. Res. 758.</text>
      <reference ref="CR H10096-10117" label="consideration"/>
    </action>
    <action datetime="2019-12-11T18:18:18-05:00">
      <text>The rule provides for consideration of H.R. 3, under a structured rule, with 4 hours of general debate. The rule provides for consideration of H.R. 5038 under a closed rule, with 1 hour of general debate. The rule provides for consideration of the conference report to accompany S. 1790 with 1 hour of debate.</text>
    </action>
    <action datetime="2019-12-11T18:18:47-05:00">
      <text>House resolved itself into the Committee of the Whole House on the state of the Union pursuant to H. Res. 758 and Rule XVIII.</text>
    </action>
    <action datetime="2019-12-11T18:18:48-05:00">
      <text>The Speaker designated the Honorable Donald M. Payne, Jr. to act as Chairman of the Committee.</text>
    </action>
    <action datetime="2019-12-11T18:19:24-05:00">
      <text>GENERAL DEBATE - The Committee of the Whole proceeded with four hours of general debate on H.R. 3.</text>
    </action>
    <action datetime="2019-12-11T21:19:59-05:00">
      <text>Mr. Scott (VA) moved that the Committee rise.</text>
    </action>
    <action datetime="2019-12-11T21:20:24-05:00">
      <text>On motion that the Committee rise Agreed to by voice vote.</text>
    </action>
    <action datetime="2019-12-11T21:20:45-05:00">
      <text>Committee of the Whole House on the state of the Union rises leaving H.R. 3 as unfinished business.</text>
    </action>
    <action datetime="2019-12-12T09:14:53-05:00">
      <text>Considered as unfinished business.</text>
      <reference ref="CR H10129-10225" label="consideration"/>
      <reference ref="CR H10141-10167" label="text"/>
    </action>
    <action datetime="2019-12-12T09:15:03-05:00">
      <text>The House resolved into Committee of the Whole House on the state of the Union for further consideration.</text>
    </action>
    <action datetime="2019-12-12T09:15:58-05:00">
      <text>GENERAL DEBATE - The Committee of the Whole proceeded with one hour of further debate on H.R. 3.</text>
    </action>
    <action datetime="2019-12-12T10:49:44-05:00">
      <text>DEBATE - Pursuant to the provisions of H.Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Walden amendment No. 1.</text>
    </action>
    <action datetime="2019-12-12T11:02:48-05:00">
      <text>POSTPONED PROCEEDINGS - At the conclusion of debate on the Walden amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the noes had prevailed. Mr. Walden demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.</text>
    </action>
    <action datetime="2019-12-12T11:03:18-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Tonko amendment No. 2.</text>
    </action>
    <action datetime="2019-12-12T11:15:09-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Peters amendment No. 3.</text>
    </action>
    <action datetime="2019-12-12T11:25:13-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Kennedy amendment No. 4.</text>
    </action>
    <action datetime="2019-12-12T11:34:51-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the O'Halleran amendment No. 5.</text>
    </action>
    <action datetime="2019-12-12T11:45:04-05:00">
      <text>POSTPONED PROCEEDINGS - At the conclusion of debate on the O'Halleran amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. O'Halleran demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.</text>
    </action>
    <action datetime="2019-12-12T11:45:16-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Kennedy amendment No. 6.</text>
    </action>
    <action datetime="2019-12-12T11:54:09-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Gottheimer amendment No. 7.</text>
    </action>
    <action datetime="2019-12-12T12:04:36-05:00">
      <text>POSTPONED PROCEEDINGS - At the conclusion of debate on the Gottheimer amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Gottheimer demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.</text>
    </action>
    <action datetime="2019-12-12T12:05:20-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Axne amendment No. 8.</text>
    </action>
    <action datetime="2019-12-12T12:13:13-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Finkenauer amendment No. 9.</text>
    </action>
    <action datetime="2019-12-12T12:21:28-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Luria amendment No. 10.</text>
    </action>
    <action datetime="2019-12-12T12:27:55-05:00">
      <text>POSTPONED PROCEEDINGS - At the conclusion of debate on the Luria amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Walden demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.</text>
    </action>
    <action datetime="2019-12-12T12:28:05-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Cunningham amendment No. 11.</text>
    </action>
    <action datetime="2019-12-12T12:36:05-05:00">
      <text>POSTPONED PROCEEDINGS - At the conclusion of debate on the Cunningham amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Roe (TN) demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.</text>
    </action>
    <action datetime="2019-12-12T12:36:42-05:00">
      <text>DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Houlahan amendment No. 12.</text>
    </action>
    <action datetime="2019-12-12T12:46:55-05:00">
      <text>UNFINISHED BUSINESS - The Chair announced that the unfinished business was on adoption of amendments, which were debated earlier and on which further proceedings had been postponed.</text>
    </action>
    <action datetime="2019-12-12T13:41:54-05:00">
      <text>The House rose from the Committee of the Whole House on the state of the Union to report H.R. 3.</text>
    </action>
    <action datetime="2019-12-12T13:42:53-05:00">
      <text>The previous question was ordered pursuant to the rule.</text>
    </action>
    <action datetime="2019-12-12T13:43:11-05:00">
      <text>The House adopted the amendments en gross as agreed to by the Committee of the Whole House on the state of the Union.</text>
    </action>
    <action datetime="2019-12-12T13:43:44-05:00">
      <text>Mr. Upton moved to recommit with instructions to the Committee on Energy and Commerce.</text>
      <reference ref="CR H10223" label="text"/>
    </action>
    <action datetime="2019-12-12T13:44:05-05:00">
      <text>DEBATE - The House proceeded with 10 minutes of debate on the Upton motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to change the effective date of the Act until the Secretary of Health and Human Services certifies that the implementation of the provisions in the bill are not projected to result in fewer new drug applications with respect to unmet medical needs and life saving cures.</text>
    </action>
    <action datetime="2019-12-12T13:56:59-05:00">
      <text>The previous question on the motion to recommit with instructions was ordered without objection.</text>
    </action>
    <action datetime="2019-12-12T14:03:26-05:00">
      <text>On motion to recommit with instructions Failed by the Yeas and Nays: 196 - 226 (Roll no. 681).</text>
    </action>
    <vote how="roll" type="vote" roll="682" datetime="2019-12-12T14:09:56-05:00" where="h" result="pass" state="PASS_OVER:HOUSE">
      <text>On passage Passed by the Yeas and Nays: 230 - 192 (Roll no. 682).</text>
    </vote>
    <action datetime="2019-12-12T14:09:58-05:00">
      <text>Motion to reconsider laid on the table Agreed to without objection.</text>
    </action>
    <action datetime="2019-12-16">
      <text>Received in the Senate.</text>
    </action>
    <action datetime="2020-08-13">
      <text>Read the first time. Placed on Senate Legislative Calendar under Read the First Time.</text>
    </action>
    <calendar datetime="2020-09-08" calendar="Senate Legislative" under="General Orders" number="521">
      <text>Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.</text>
    </calendar>
  </actions>
  <committees>
    <committee code="HSED" name="House Education and the Workforce" subcommittee="" activity="Reporting, Markup, Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Reporting, Markup, Referral"/>
    <committee code="HSWM02" name="House Ways and Means" subcommittee="Health" activity="Referral"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Reporting, Markup, Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Discharged, Hearings, Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="2296" relation="unknown"/>
    <bill session="116" type="h" number="3343" relation="unknown"/>
    <bill session="116" type="h" number="3347" relation="unknown"/>
    <bill session="116" type="h" number="3398" relation="unknown"/>
    <bill session="116" type="h" number="4455" relation="unknown"/>
    <bill session="116" type="h" number="4618" relation="unknown"/>
    <bill session="116" type="h" number="4619" relation="unknown"/>
    <bill session="116" type="h" number="4629" relation="unknown"/>
    <bill session="116" type="h" number="4633" relation="unknown"/>
    <bill session="116" type="h" number="4649" relation="unknown"/>
    <bill session="116" type="h" number="4650" relation="unknown"/>
    <bill session="116" type="h" number="4661" relation="unknown"/>
    <bill session="116" type="h" number="4663" relation="unknown"/>
    <bill session="116" type="h" number="4665" relation="unknown"/>
    <bill session="116" type="h" number="4666" relation="unknown"/>
    <bill session="116" type="h" number="4669" relation="unknown"/>
    <bill session="116" type="h" number="4675" relation="unknown"/>
    <bill session="116" type="h" number="4676" relation="unknown"/>
    <bill session="116" type="h" number="4768" relation="unknown"/>
    <bill session="116" type="h" number="4835" relation="unknown"/>
    <bill session="116" type="h" number="5281" relation="unknown"/>
    <bill session="116" type="h" number="5357" relation="unknown"/>
    <bill session="116" type="h" number="5688" relation="unknown"/>
    <bill session="116" type="s" number="1260" relation="unknown"/>
    <bill session="116" type="s" number="3376" relation="unknown"/>
    <bill session="116" type="hr" number="758" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Accounting and auditing"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Adult education and literacy"/>
    <term name="Cancer"/>
    <term name="Centers for Disease Control and Prevention (CDC)"/>
    <term name="Child care and development"/>
    <term name="Child health"/>
    <term name="Civil actions and liability"/>
    <term name="Congressional oversight"/>
    <term name="Criminal justice information and records"/>
    <term name="Dental care"/>
    <term name="Department of Health and Human Services"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Education of the disadvantaged"/>
    <term name="Education programs funding"/>
    <term name="Elementary and secondary education"/>
    <term name="Employee hiring"/>
    <term name="Employment and training programs"/>
    <term name="Executive agency funding and structure"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Health care quality"/>
    <term name="Health facilities and institutions"/>
    <term name="Health information and medical records"/>
    <term name="Health personnel"/>
    <term name="Health programs administration and funding"/>
    <term name="Health promotion and preventive care"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Hearing, speech, and vision care"/>
    <term name="Indian social and development programs"/>
    <term name="Inflation and prices"/>
    <term name="Manufacturing"/>
    <term name="Marketing and advertising"/>
    <term name="Medicaid"/>
    <term name="Medical education"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Medicare"/>
    <term name="Mental health"/>
    <term name="Minority health"/>
    <term name="National Institutes of Health (NIH)"/>
    <term name="Performance measurement"/>
    <term name="Prescription drugs"/>
    <term name="Public contracts and procurement"/>
    <term name="Public-private cooperation"/>
    <term name="Research administration and funding"/>
    <term name="Rural conditions and development"/>
    <term name="Sales and excise taxes"/>
    <term name="Sex and reproductive health"/>
    <term name="State and local government operations"/>
    <term name="U.S. territories and protectorates"/>
    <term name="Veterans' education, employment, rehabilitation"/>
    <term name="Women's health"/>
  </subjects>
  <amendments>
    <amendment number="h722"/>
    <amendment number="h721"/>
    <amendment number="h720"/>
    <amendment number="h719"/>
    <amendment number="h718"/>
    <amendment number="h717"/>
    <amendment number="h716"/>
    <amendment number="h715"/>
    <amendment number="h714"/>
    <amendment number="h713"/>
    <amendment number="h712"/>
    <amendment number="h711"/>
  </amendments>
  <summary date="2021-05-04T17:43:18Z" status="Passed House">Elijah E. Cummings Lower Drug Costs Now Act

This bill establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health.

TITLE I--LOWERING PRICES THROUGH FAIR DRUG PRICE NEGOTIATION

The bill requires the Department of Health and Human Services (HHS) to negotiate prices for certain drugs. (Under current law, HHS may not negotiate the prices of covered drugs under the Medicare prescription drug benefit.)

Specifically, HHS must negotiate maximum prices for (1) insulin products; (2) with respect to&#160;2023, at least 25 single-source, brand-name drugs that do not have generic competition and that are among either the 125 drugs that account for the greatest national spending or the 125 drugs that account for the greatest spending under the Medicare prescription drug benefit and Medicare Advantage (MA); (3) beginning in 2024, at least 50 such single-source, brand-name drugs; and (4) newly approved single-source, brand-name drugs that meet or exceed a specified price threshold and that HHS determines are likely to meet the spending criteria. The negotiated prices must be offered under Medicare and MA and may also be offered under private health insurance unless the insurer opts out.

The negotiated maximum price may not exceed (1) 120% of the average price in Australia, Canada, France, Germany, Japan, and the United Kingdom; or (2) if such information is not available, 85% of the U.S. average manufacturer price. Drug manufacturers that fail to comply with the bill's negotiation requirements are subject to civil and tax penalties.

TITLE II--MEDICARE PARTS B AND D PRESCRIPTION DRUG INFLATION REBATES

The bill also requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare &amp; Medicaid Services (CMS) for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation.

TITLE III--PART D IMPROVEMENTS AND MAXIMUM OUT-OF-POCKET CAP FOR MEDICARE BENEFICIARIES

The bill reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit. Additionally, prescription drug plan sponsors must allow certain beneficiaries to make coinsurance payments in periodic installments, in accordance with CMS requirements.

TITLE IV--DRUG PRICE TRANSPARENCY

Drug manufacturers must report, subject to civil penalties, specified information for certain drugs that cost $100 or more and that are covered under Medicare or Medicaid, based on the rate of price or spending increases. Among other things, manufacturers must report a qualifying price increase at least 30 days before the effective date of the increase; HHS must publish the information on its website the day the increase takes effect.

TITLE V--PROGRAM IMPROVEMENTS FOR MEDICARE LOW-INCOME BENEFICIARIES

The bill expands eligibility for certain premium and cost-sharing subsidies for low-income beneficiaries under the Medicare prescription drug benefit. For example, the bill (1) raises the maximum allowable income for beneficiaries to qualify, and (2) allows certain residents of U.S. territories to automatically qualify.

TITLE VI--PROVIDING FOR DENTAL, VISION, AND HEARING COVERAGE UNDER THE MEDICARE PROGRAM

The bill also expands Medicare coverage to include (1) dentures and dental and oral health services, including basic and major treatments (as determined by the CMS) as well as specified preventive and screening services; (2) hearing aids and hearing rehabilitation and treatment services; and (3) eyeglasses, contact lenses, and vision services, including routine eye examinations and contact lens fittings.

TITLE VII--NIH, FDA, AND OPIOIDS FUNDING

The bill provides additional funds for several public health programs. Among other things, the bill (1) provides specified funds for innovation projects at the National Institutes of Health through FY2030 and for innovation projects at the Food and Drug Administration through FY2029; and (2) establishes the Opioid Epidemic Response Fund to support HHS programs and initiatives, including the State Opioid Response Grant Program.

Additionally, HHS must take a series of actions relating to health care administrative costs. Specifically, HHS must develop a strategy and take associated action to reduce unnecessary costs and administrative burdens in the health care system, including Medicare, Medicaid, and the private health-insurance market, by at least half over a period of 10 years. HHS must also award grants so that states may establish commissions targeting such costs.

TITLE VIII--MISCELLANEOUS

The bill also establishes and revises several other health care programs and requirements.

For example, the bill (1) expands guaranteed issue rights with respect to Medigap policies (Medicare supplemental health-insurance policies); (2) provides specified funds for the Community Health Centers Fund through FY2025; (3) establishes grant programs to support mental health and trauma services in schools, as well as career development programs for health professionals; and (4) requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid.

Additionally, the CMS must issue regulations that require direct-to-consumer television advertisements for all covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment. (On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect July 9, 2019; however, a federal court blocked implementation, citing a lack of statutory authority.)</summary>
  <committee-reports>
    <report>H. Rept. 116-324,Part 3</report>
    <report>H. Rept. 116-324,Part 1</report>
    <report>H. Rept. 116-324,Part 2</report>
  </committee-reports>
</bill>
